Johnson&Johnson announced that it has asked the Food and Drug Administration to authorize the emergency use of its single-dose Covid vaccine Thursday.
The vaccine is believed to be 77 percent effective in the world’s first single-shot Covid vaccine and if approved, the third vaccine against the viral illness in the US.
Furthermore, Johnson&Johnson’s jab doesn’t require to be shipped or stored in freezing conditions.
“Today’s submission for Emergency Use Authorization of our investigation single-shot Covid-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic,” the company chief scientific officer Paul Stoffels said.
“Upon authorization of our investigational Covid-19 vaccine for emergency use, we are ready to begin shipping.”
The official added that Johnson&Johnson has rolling submissions with some global health agencies including one with the European Medicines Agency expected in the upcoming weeks.